Daniel Guthy

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang et al. · Molecular Cancer Therapeutics · 2011 · 529 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Christine Fritsch, Alan Huang, Christian Chatenay‐Rivauday et al. · Molecular Cancer Therapeutics · 2014 · 496 citations

Medicine, Oncology, Pharmacology +16

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Andreas Weiss, Edwige Lorthiois, Louise Barys et al. · Cancer Discovery · 2022 · 134 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Saskia M. Brachmann, Julia Kleylein-Sohn, Swann Gaulis et al. · Molecular Cancer Therapeutics · 2012 · 120 citations · Full text

Life Sciences, Oncology, Pharmacology +17

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS^G12C for the Treatment of Solid Tumors

Edwige Lorthiois, Marc Gerspacher, Kim S. Beyer et al. · Journal of Medicinal Chemistry · 2022 · 95 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17